Arbutus Biopharma Corporation ABUS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $191.45M+1,259% | $14.08M-3.6% | $14.61M-5.3% | $15.42M+141% | $6.4M+3.8% | ||
| $20.4M-19.2% | $25.24M-13.1% | $29.05M-22.6% | $37.54M-21.1% | $47.59M-11.9% | ||
| $15.95M+0.4% | $15.89M-6.0% | $16.92M-8.1% | $18.41M-18.6% | $22.63M+2.4% | ||
| —— | —— | —— | —— | —— | ||
| $12.8M-49.1% | $25.17M+0.8% | $24.97M-12.4% | $28.49M+77.1% | $16.09M+333% | ||
| $35M-33.0% | $52.24M-14.9% | $61.41M-18.1% | $75M-15.8% | $89.06M+8.0% | ||
| $35M-33.0% | $52.24M-14.9% | $61.41M-18.1% | $75M-15.8% | $89.06M+8.0% | ||
| $156.45M+510% | -$38.16M+18.5% | -$46.8M+21.5% | -$59.58M+27.9% | -$82.66M-8.3% | ||
| 81.7%+353pp | -271%+49.5pp | -320.4%+66.1pp | -386.5%+904pp | -1,290.9%-54.1pp | ||
| $86K-11.3% | $97K-11.0% | $109K-5.2% | $115K-5.0% | $121K-11.7% | ||
| $3.69M-9.4% | $4.07M-12.6% | $4.66M-14.6% | $5.45M-12.6% | $6.24M-5.3% | ||
| $4.27M-8.3% | $4.66M+2.9% | $4.53M-15.1% | $5.33M-12.4% | $6.08M-4.9% | ||
| $160.72M+580% | -$33.5M+20.8% | -$42.28M+22.1% | -$54.25M+29.1% | -$76.57M-9.5% | ||
| 84%+322pp | -237.9%+51.6pp | -289.4%+62.5pp | -351.9%+844pp | -1,195.9%-62.8pp | ||
| $0.83+588% | -$0.17+26.1% | -$0.23+20.7% | -$0.29+29.3% | -$0.41-7.9% | ||
| $0.84+594% | -$0.17+26.1% | -$0.23+20.7% | -$0.29+29.3% | -$0.41-7.9% | ||
| 771M+0.6% | 766.5M+0.8% | 760.5M+0.4% | 757.7M+0.6% | 753.4M+2.0% | ||
| 768.7M+0.4% | 765.6M+0.8% | 759.6M+0.4% | 756.9M+0.5% | 753.4M+2.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.83M-155% | -$716.25K-280% | $397.5K-73.7% | $1.51M-42.4% | ||
| $160.69M+580% | -$33.46M+20.9% | -$42.32M+21.8% | -$54.13M+29.1% | -$76.37M-9.7% | ||
| —— | —— | —— | —— | —— | ||
| -$1K-107% | $14K+170% | -$20K-567% | -$3K+90.6% | -$32K+34.7% | ||
| $156.45M+510% | -$38.16M+18.5% | -$46.8M+21.5% | -$59.58M+27.9% | -$82.66M-8.3% | ||
| $156.57M+515% | -$37.72M+18.2% | -$46.11M+21.3% | -$58.56M+28.0% | -$81.29M-8.5% | ||
| $156.57M+515% | -$37.72M+18.2% | -$46.11M+21.3% | -$58.56M+28.0% | -$81.29M-8.5% | ||
| 81.8%+350pp | -267.8%+47.8pp | -315.7%+64.2pp | -379.9%+890pp | -1,269.5%-55.4pp | ||
| $156.45M+510% | -$38.16M+18.5% | -$46.8M+21.5% | -$59.58M+27.9% | -$82.66M-8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arbutus Biopharma Corporation's revenue?
- Arbutus Biopharma Corporation (ABUS) generated $191.4M in revenue over the trailing twelve months, up 2889.9% year over year.
- Is Arbutus Biopharma Corporation profitable?
- Arbutus Biopharma Corporation reported $160.7M in net income over the trailing twelve months, a 84.0% net margin.
- What is Arbutus Biopharma Corporation's earnings per share?
- Arbutus Biopharma Corporation's diluted EPS over the trailing twelve months is $0.83.
- Where does Arbutus Biopharma Corporation's income statement data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
